Equities
Health CarePharmaceuticals and Biotechnology
  • Price (USD)18.69
  • Today's Change-1.00 / -5.08%
  • Shares traded302.38k
  • 1 Year change-32.43%
  • Beta1.0639
Data delayed at least 15 minutes, as of Jun 14 2024 21:00 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Zai Lab Ltd is a holding company mainly engaged in the biopharmaceutical field. The Company is focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including oncology, autoimmune and infectious diseases fields. The Company has a broad pipeline of proprietary drug candidates that range from discovery stage to late-stage clinical programs. These include Niraparib (ZL-2306), ZL-2103, ZL-1101 and others.

  • Revenue in USD (TTM)291.07m
  • Net income in USD-338.95m
  • Incorporated2013
  • Employees2.18k
  • Location
    Zai Lab Ltd4560 Jinke Road, Bldg. 1, 4/F, PudongSHANGHAI 201210ChinaCHN
  • Phone+86 2 161632588
  • Fax+86 2 161632570
  • Websitehttps://www.zailaboratory.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Arvinas Inc71.30m-354.80m1.76bn445.00--2.88--24.64-6.05-6.051.228.930.0597--12.08160,224.70-29.59-22.01-37.90-26.47-----495.65-316.55----0.0012---40.2640.53-30.02--0.4852--
Catalyst Pharmaceuticals Inc411.35m65.12m1.78bn167.0027.973.1717.644.320.53840.53843.604.760.78063.608.762,463,156.0012.3625.4214.1929.8186.7485.6315.8330.874.83--0.000.0085.90280.39-14.05--20.21--
Keros Therapeutics Inc234.00k-160.30m1.78bn141.00--3.92--7,611.54-5.14-5.140.007512.590.0005----1,720.59-36.84-35.95-38.35-38.07-----68,505.13-1,237.26----0.00-----56.77-46.15--62.57--
Zai Lab Ltd - ADR291.07m-338.95m1.89bn2.18k--2.39--6.48-3.50-3.503.007.830.26972.845.61133,825.80-31.41-37.72-36.81-42.7262.8664.75-116.45-282.444.43--0.0596--24.03360.0324.51---3.45--
Maravai Lifesciences Holdings Inc274.10m-131.04m1.89bn570.00--4.61--6.91-0.9917-0.99172.081.630.14582.935.90421,690.80-8.4912.67-11.2915.4644.0374.79-58.2737.3210.47-2.020.41690.00-67.2818.47-154.05--78.56--
Immunocore Holdings PLC - ADR265.83m-59.44m1.92bn497.00--5.32--7.24-1.20-1.205.277.230.34860.4065.60534,860.40-7.80-27.55-9.40-36.8299.60---22.36-97.125.94--0.5489--43.0551.23-5.22--2.85--
Protagonist Therapeutics Inc314.95m162.11m1.96bn124.0013.583.4912.016.222.462.465.259.560.7248--2.102,812,080.0037.30-35.9040.23-41.36----51.47-332.81----0.00--125.7314.1738.02--4.62--
Vera Therapeutics Inc0.00-94.30m1.97bn55.00--5.55-----2.04-2.040.006.490.00----0.00-29.99---31.92--------------0.124-------7.79------
Amphastar Pharmaceuticals Inc676.21m154.69m1.98bn1.76k13.952.949.852.932.902.9012.7013.770.5762.795.66383,991.5013.339.4215.7511.5654.7347.8323.1415.231.728.480.46920.0029.1416.9450.51---4.00--
Rocket Pharmaceuticals Inc0.00-249.31m1.98bn268.00--4.49-----2.87-2.870.004.870.00----0.00-49.16-35.26-52.49-37.49------------0.0458-------10.70--62.52--
Novavax Inc996.61m-398.71m2.02bn1.54k------2.03-3.18-3.188.46-6.180.688214.7514.85645,890.50-27.53-46.06-460.95-269.5763.04---40.01-75.940.8843-27.04-----50.3695.6817.16--108.28--
Kymera Therapeutics Inc79.41m-154.59m2.04bn186.00--2.87--25.72-2.50-2.501.2911.590.1072--29.69424,668.40-20.86-23.03-22.67-27.64-----194.67-207.82----0.0032--67.84--5.07--91.01--
Beam Therapeutics Inc360.91m-134.74m2.05bn436.00--2.24--5.67-1.74-1.744.5411.100.2681----827,777.50-10.01-24.54-11.79-29.26-----37.33-211.96----0.00--520.01--54.16--20.78--
Vericel Corp207.78m451.00k2.06bn314.004,423.648.77380.629.890.00960.00964.354.820.66844.384.71661,719.800.1451-3.070.1621-3.5069.5067.870.2171-4.494.83--0.0007--20.1716.8080.96--59.35--
Data as of Jun 14 2024. Currency figures normalised to Zai Lab Ltd's reporting currency: US Dollar USD

Institutional shareholders

28.73%Per cent of shares held by top holders
HolderShares% Held
Wellington Management Co. LLPas of 23 May 20246.29m6.34%
Capital Research & Management Co. (World Investors)as of 31 Mar 20245.68m5.73%
Janus Henderson Investors US LLCas of 31 Mar 20244.42m4.46%
Woodline Partners LPas of 31 Mar 20242.60m2.62%
Viking Global Investors LPas of 31 Mar 20242.05m2.06%
T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 20241.65m1.66%
BAMCO, Inc.as of 31 Mar 20241.60m1.61%
Segantii Capital Management Ltd.as of 31 Mar 20241.56m1.57%
Fidelity Management & Research Co. LLCas of 31 Mar 20241.36m1.37%
Rock Springs Capital Management LPas of 31 Mar 20241.30m1.31%
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.